Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katrine L Henriksen

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Acta Oncologica (Stockholm, Sweden)|May 10, 2008
Development of new predictive markers for endocrine therapy and resistance in breast cancerKatrine L Henriksen, Katrine Sonne-Hansen, Tove Kirkegaard, et al.
Acta Oncologica (Stockholm, Sweden)|January 29, 2009
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancerKatrine L Henriksen, Birgitte B Rasmussen, Anne E Lykkesfeldt, et al.
Journal of Clinical Pathology|June 16, 2006
Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarraysKatrine L Henriksen, Birgitte B Rasmussen, Anne E Lykkesfeldt, et al.
The Journal of Biological Chemistry|October 28, 2010
Pancreatic bicarbonate secretion involves two proton pumpsIvana Novak, Jing Wang, Katrine L Henriksen, et al.
BMC Cancer|June 18, 2009
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancerAnne E Lykkesfeldt, Katrine L Henriksen, Birgitte B Rasmussen, et al.
Breast (Edinburgh, Scotland)|August 3, 2012
Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapyMathilde S Larsen, Karsten Bjerre, Anne E Lykkesfeldt, et al.
Acta Oncologica (Stockholm, Sweden)|April 3, 2012
Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapyMathilde S Larsen, Karsten Bjerre, Anita Giobbie-Hurder, et al.
Acta Oncologica (Stockholm, Sweden)|December 5, 2012
Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancerChristina Bjerre, Ann Knoop, Karsten Bjerre, et al.
The Lancet. Oncology|December 18, 2007
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trialBirgitte B Rasmussen, Meredith M Regan, Anne E Lykkesfeldt, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Acta Oncologica (Stockholm, Sweden)|May 10, 2008
Development of new predictive markers for endocrine therapy and resistance in breast cancerKatrine L Henriksen, Katrine Sonne-Hansen, Tove Kirkegaard, et al.
Acta Oncologica (Stockholm, Sweden)|January 29, 2009
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancerKatrine L Henriksen, Birgitte B Rasmussen, Anne E Lykkesfeldt, et al.
Journal of Clinical Pathology|June 16, 2006
Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarraysKatrine L Henriksen, Birgitte B Rasmussen, Anne E Lykkesfeldt, et al.
The Journal of Biological Chemistry|October 28, 2010
Pancreatic bicarbonate secretion involves two proton pumpsIvana Novak, Jing Wang, Katrine L Henriksen, et al.
BMC Cancer|June 18, 2009
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancerAnne E Lykkesfeldt, Katrine L Henriksen, Birgitte B Rasmussen, et al.
Breast (Edinburgh, Scotland)|August 3, 2012
Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapyMathilde S Larsen, Karsten Bjerre, Anne E Lykkesfeldt, et al.
Acta Oncologica (Stockholm, Sweden)|April 3, 2012
Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapyMathilde S Larsen, Karsten Bjerre, Anita Giobbie-Hurder, et al.
Acta Oncologica (Stockholm, Sweden)|December 5, 2012
Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancerChristina Bjerre, Ann Knoop, Karsten Bjerre, et al.
The Lancet. Oncology|December 18, 2007
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trialBirgitte B Rasmussen, Meredith M Regan, Anne E Lykkesfeldt, et al.
Pageof 1